Afficher la notice abrégée

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGALVIN, Angeline
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCOURTINARD, Coralie
dc.contributor.authorBOUTEILLER, Fanny
dc.contributor.authorGOURGOU, Sophie
dc.contributor.authorDALENC, Florence
dc.contributor.authorJACOT, William
dc.contributor.authorARNEDOS, Monica
dc.contributor.authorBAILLEUX, Caroline
dc.contributor.authorDIERAS, Veronique
dc.contributor.authorPETIT, Thierry
dc.contributor.authorEMILE, George
dc.contributor.authorDUBRAY-LONGERAS, Pascale
dc.contributor.authorFRENEL, Jean-Sebastien
dc.contributor.authorBACHELOT, Thomas
dc.contributor.authorMAILLIEZ, Audrey
dc.contributor.authorBRAIN, Etienne
dc.contributor.authorDESMOULINS, Isabelle
dc.contributor.authorMASSARD, Vincent
dc.contributor.authorPATSOURIS, Anne
dc.contributor.authorGONCALVES, Anthony
dc.contributor.authorGRINDA, Thomas
dc.contributor.authorDELALOGE, Suzette
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.date.accessioned2024-02-20T08:22:32Z
dc.date.available2024-02-20T08:22:32Z
dc.date.issued2024-01-01
dc.identifier.issn0959-8049en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188248
dc.description.abstractEnAIM: To describe first-line treatment patterns, overall survival (OS) and real-world progression-free survival (rwPFS) in young women (<40) with metastatic breast cancer (mBC), as compared to women aged 40-69. MATERIALS AND METHODS: Data on adult women diagnosed with mBC (2008-2017) were extracted from the ESME mBC database (NCT03275311) which includes consecutive patients starting first-line metastatic treatment in one of the 18 French Comprehensive cancer centers. We reported first-line therapeutic strategy and prognostic factors of OS and rwPFS for women aged < 40 and 40-69. RESULTS: In total, 14,897 mBC women were included (1512 aged <40). HR+ /HER2- mBC was the most frequent subtype. First-line treatment differed between young patients and older ones for HR+ /HER2- and Triple Negative (TN) mBC. Median OS for women aged < 40 and 40-69, respectively, was 46.9 and 46.2 months for HR+ /HER2- mBC; 13.5 and 15.2 for TN mBC; and, 60.7 and 55.1 for HER2 + mBC. Median rwPFS under first line treatment was 11.6 and 11.9 months for HR+ /HER2- in women aged < 40 and 40-69, respectively; 5.5 and 5.9 for TN, and, 13.3 and 12.9 for HER2 + . Factors associated with shorter OS and rwPFS were similar for both women aged < 40 and 40-69 and included ≥ 3 metastatic sites, visceral metastases, and longer MFI, with time-varying effects observed for several prognostic factors. CONCLUSION: Young women presented more frequently with TN and HER2 + subtypes and aggressive mBC than women aged 40-69 did. Prognostic factors of OS and rwPFS were quite similar between age groups and mBC subtypes.
dc.language.isoENen_US
dc.subject.enReal-word data
dc.subject.enMetastatic breast cancer
dc.subject.enSurvival endpoints
dc.title.enFirst-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
dc.title.alternativeEur J Canceren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.ejca.2023.113422en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed37977105en_US
bordeaux.journalEuropean journal of cancer (Oxford, England . 1990)en_US
bordeaux.page113422en_US
bordeaux.volume196en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04467336
hal.version1
hal.date.transferred2024-02-20T08:22:35Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=European%20journal%20of%20cancer%20(Oxford,%20England%20.%201990)&amp;rft.date=2024-01-01&amp;rft.volume=196&amp;rft.spage=113422&amp;rft.epage=113422&amp;rft.eissn=0959-8049&amp;rft.issn=0959-8049&amp;rft.au=GALVIN,%20Angeline&amp;COURTINARD,%20Coralie&amp;BOUTEILLER,%20Fanny&amp;GOURGOU,%20Sophie&amp;DALENC,%20Florence&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée